Vor Biopharma (NYSE:VOR) Major Shareholder Sells $525,000.00 in Stock

Key Points

• Reprogrammed Interchange LLC, a major shareholder of Vor Biopharma, sold 300,000 shares for $525,000, indicating a 0.88% decrease in their stake.
• Vor Biopharma's stock traded down to $1.60, with a market capitalization of $202.69 million and a twelve-month high of $3.29.
• Wall Street analysts have a consensus rating of "Moderate Buy" for VOR shares, with a target price of $6.07 as several firms restated positive ratings.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 300,000 shares of Vor Biopharma stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $1.75, for a total transaction of $525,000.00. Following the completion of the transaction, the insider directly owned 33,628,487 shares in the company, valued at $58,849,852.25. This represents a 0.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Monday, September 15th, Reprogrammed Interchange Llc sold 400,000 shares of Vor Biopharma stock. The stock was sold at an average price of $1.64, for a total transaction of $656,000.00.
• On Thursday, September 11th, Reprogrammed Interchange Llc sold 284,805 shares of Vor Biopharma stock. The stock was sold at an average price of $1.83, for a total transaction of $521,193.15.
• On Monday, September 8th, Reprogrammed Interchange Llc sold 464,421 shares of Vor Biopharma stock. The stock was sold at an average price of $1.99, for a total transaction of $924,197.79.
• On Wednesday, September 10th, Reprogrammed Interchange Llc sold 350,000 shares of Vor Biopharma stock. The stock was sold at an average price of $1.82, for a total transaction of $637,000.00.
• On Tuesday, September 9th, Reprogrammed Interchange Llc sold 449,226 shares of Vor Biopharma stock. The stock was sold at an average price of $2.00, for a total transaction of $898,452.00.
• On Friday, September 5th, Reprogrammed Interchange Llc sold 400,000 shares of Vor Biopharma stock. The stock was sold at an average price of $1.97, for a total transaction of $788,000.00.
• On Thursday, September 4th, Reprogrammed Interchange Llc sold 453,016 shares of Vor Biopharma stock. The stock was sold at an average price of $1.93, for a total transaction of $874,320.88.
• On Wednesday, September 3rd, Reprogrammed Interchange Llc sold 554,612 shares of Vor Biopharma stock. The stock was sold at an average price of $2.00, for a total transaction of $1,109,224.00.
• On Thursday, August 28th, Reprogrammed Interchange Llc sold 806,351 shares of Vor Biopharma stock. The stock was sold at an average price of $2.01, for a total transaction of $1,620,765.51.
• On Wednesday, August 27th, Reprogrammed Interchange Llc sold 611,647 shares of Vor Biopharma stock. The stock was sold at an average price of $2.01, for a total transaction of $1,229,410.47.

Vor Biopharma Stock Performance

Shares of VOR stock traded down $0.14 during trading on Monday, hitting $1.60. 6,009,423 shares of the company were exchanged, compared to its average volume of 7,617,477. The firm has a market capitalization of $202.69 million, a price-to-earnings ratio of -0.97 and a beta of 2.05. The business's 50-day simple moving average is $2.12 and its 200 day simple moving average is $1.13. Vor Biopharma Inc. has a twelve month low of $0.13 and a twelve month high of $3.29.

Institutional Trading of Vor Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC acquired a new stake in shares of Vor Biopharma in the first quarter worth $140,000. Two Sigma Investments LP lifted its stake in shares of Vor Biopharma by 18.9% in the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock worth $181,000 after buying an additional 25,930 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Vor Biopharma by 39.0% in the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company's stock worth $175,000 after buying an additional 44,252 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in shares of Vor Biopharma in the first quarter worth $100,000. Finally, Trustees of Columbia University in the City of New York acquired a new stake in shares of Vor Biopharma in the fourth quarter worth $102,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently commented on VOR. Wedbush restated an "outperform" rating on shares of Vor Biopharma in a report on Thursday, June 26th. HC Wainwright restated a "buy" rating and set a $3.00 price target on shares of Vor Biopharma in a report on Thursday, August 14th. Five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $6.07.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.